Sarepta Therapeutics Gains Approval for an Efficacy Supplement

Sarepta Therapeutics announces US FDA acceptance of an efficacy supplement to expand the Elevidys indication

Overview

Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, announced the US Food and Drug Administration (FDA) has accepted and filed the company's efficacy supplement to the Biologics License Application (BLA) for Elevidys (delandistrogene moxeparvovec-rokl) (the “Efficacy Supplement”).

The goals of the Efficacy Supplement are twofold: To expand the labelled indication for Elevidys as follows: “[Elevidys is indicated for] the treatment of Duchenne muscular dystrophy (DMD) patients with a confirmed mutation in the DMD gene.”

To convert the Elevidys accelerated approval to a traditional approval.

FDA Review

The FDA has granted the Efficacy Supplement a Priority Review with a review goal date of June 21, 2024. The Agency has also confirmed they are not planning to hold an advisory committee meeting to discuss the supplement.

From CEO- Sarepta Therapeutics

"We are pleased to announce that FDA has accepted and filed Sarepta’s Efficacy Supplement to evaluate broadening the approved indication of Elevidys by removing age and ambulation restrictions and converting the approval from accelerated to traditional,” said Doug Ingram, president and chief executive officer, Sarepta Therapeutics. “We are particularly grateful for the Division’s prompt engagement and commitment to expediency by granting priority review and setting a June 21 review goal date. Understanding that every day matters to families living with Duchenne, we will work with our regulatory counterparts to successfully complete this review as rapidly as possible."

Partnership for Duchenne community

• As part of a collaboration agreement signed in 2019, Sarepta Therapeutics is working with Roche to transform the future for the Duchenne community, enabling those living with the disease to maintain and protect their muscle function. 

• Sarepta is responsible for regulatory approval and commercialization of Elevidys in the US, as well as manufacturing. 

• Roche is responsible for regulatory approvals and bringing Elevidys to patients across the rest of the world.

Elevidys

• Elevidys (delandistrogene moxeparvovec-rokl) is a single-dose, adeno-associated virus (AAV) based gene transfer therapy for intravenous infusion designed to address the underlying genetic cause of Duchenne muscular dystrophy – mutations or changes in the dystrophin gene that result in the lack of dystrophin protein – through the delivery of a transgene that codes for the targeted production of Elevidys micro-dystrophin in skeletal muscle. 

• Elevidys is a one-time infusion indicated for the treatment of ambulatory paediatric patients aged 4 through 5 years with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene and is approved under accelerated approval based on expression of Elevidys micro-dystrophin in skeletal muscle observed in patients treated with Elevidys. 

• Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials. 

• Elevidys has met the full statutory standards for safety and effectiveness and as such is not considered investigational or experimental.

• Elevidys has been evaluated in four clinical studies: SRP-9001-101, SRP-9001-102, SRP-9001-103 (ENDEAVOR) and SRP-9001-301 (EMBARK). 

• Accelerated approval of Elevidys was primarily based on data from SRP-9001-102 and SRP-9001-103. The EMBARK study serves as the postmarketing confirmatory trial.

Sarepta for Rare Diseases

Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. The company hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programmes in various stages of development.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!